Bolt Biotherapeutics, Inc.
BOLT- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001641281
In the last 90 days, Bolt Biotherapeutics, Inc. insiders filed 2 open-market purchases and 3 sales; 23 institutions reported holding it in 13F filings for Q2 2026, worth $2.31M in total; no superinvestor holds it.
13F holders, Q2 2026
Institutional positions in Bolt Biotherapeutics, Inc. as of Jun 30, 2026. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 23
- −1 vs. Q1 2026
- Shares held
- 596.5K
- −16.7K (−2.7%) vs. Q1 2026
- Total value
- $2.31M
- −$178.2K (−7.2%) vs. Q1 2026
- New holders
- 2
- 5 more added
- Sold out
- 3
- 4 more reduced
Compare with Q1 2026: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting BOLT on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 23 | $2.31M |
| Q1 2026 | 24 | $2.49M |
| Q4 2025 | 21 | $3.30M |
| Q3 2025 | 24 | $4.28M |
| Q2 2025 | 25 | $5.10M |
| Q1 2025 | 30 | $7.33M |
| Q4 2024 | 38 | $9.99M |
| Q3 2024 | 32 | $12.2M |
| Q2 2024 | 37 | $17.0M |
| Q1 2024 | 39 | $33.7M |
| Q4 2023 | 40 | $27.1M |
| Q3 2023 | 35 | $25.5M |
| Q2 2023 | 40 | $32.1M |
| Q1 2023 | 41 | $32.5M |
| Q4 2022 | 44 | $26.8M |
| Q3 2022 | 56 | $39.7M |
| Q2 2022 | 62 | $54.8M |
| Q1 2022 | 66 | $84.8M |
| Q4 2021 | 62 | $164.6M |
| Q3 2021 | 72 | $449.1M |
| Q2 2021 | 61 | $513.8M |
| Q1 2021 | 70 | $1.04B |
Institutions, Q2 2026
Shares, value and share of portfolio for each institution holding Bolt Biotherapeutics, Inc.; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Sofinnova Investments, Inc. | 137,721 | $530.2K | 0.03% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 98,625 | $379.7K | 0.00% | +21,400+27.7% | Added |
| Vivo Capital, LLC | 72,414 | $278.8K | 0.03% | 00.0% | Unchanged |
| Citadel Advisors LLC | 56,903 | $219.1K | 0.00% | +46,794+462.9% | Added |
| T3 Companies, LLC | 38,000 | $146.3K | 0.17% | 00.0% | Unchanged |
| Board of Trustees of The Leland Stanford Junior University | 35,977 | $138.5K | 0.03% | 00.0% | Unchanged |
| Pfizer Inc | 31,305 | $133.8K | 0.08% | 00.0% | Unchanged |
| Lynx1 Capital Management LP | 30,800 | $118.6K | 0.01% | 00.0% | Unchanged |
| Nano Cap New Millennium Growth Fund L P | 27,500 | $105.9K | 0.08% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 19,119 | $73.6K | 0.00% | −9,672−33.6% | Reduced |
| Shay Capital LLC | 15,438 | $59.4K | 0.01% | +533+3.6% | Added |
| BlackRock, Inc. | 9,711 | $37.4K | 0.00% | 00.0% | Unchanged |
| Vanguard Capital Management LLC | 7,060 | $27.2K | 0.00% | 00.0% | Unchanged |
| Nan Fung Group Holdings Ltd | 5,000 | $19.3K | 0.01% | −24,250−82.9% | Reduced |
| Morgan Stanley | 3,145 | $12.1K | 0.00% | −44−1.4% | Reduced |
| Vanguard Fiduciary Trust Co | 3,095 | $11.9K | 0.00% | 00.0% | Unchanged |
| GWM Advisors LLC | 2,530 | $9.74K | 0.00% | +2,530 | New |
| Tower Research Capital LLC (TRC) | 1,710 | $6.58K | 0.00% | +617+56.5% | Added |
| UBS Group AG | 255 | $982 | 0.00% | −532−67.6% | Reduced |
| SBI Securities Co., Ltd. | 130 | $501 | 0.00% | +120+1,200.0% | Added |
| JPMorgan Chase & Co | 42 | $165 | 0.00% | 00.0% | Unchanged |
| Citigroup Inc | 41 | $158 | 0.00% | +41 | New |
| Barclays PLC | 6 | $23 | 0.00% | 00.0% | Unchanged |
| Pivotal bioVenture Partners Investment Advisor LLC | 0 | $0 | 0.00% | −42,581−100.0% | Sold out |
| Susquehanna International Group, LLP | 0 | $0 | 0.00% | −11,657−100.0% | Sold out |
| Vanguard Global Advisers, LLC | 0 | $0 | 0.00% | −24−100.0% | Sold out |